Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
131I-apamistamab-led HSCT in R/R AML
NCT07157514Phase 3Not yet recruiting
- Sponsor
- Actinium Pharmaceuticals, Inc.
- Start
- Jan 2026
- Primary completion
- Feb 2029
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 3 trial of apamistamab in acute myeloid leukemia (AML), sponsored by Actinium Pharmaceuticals, Inc.. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
apamistamab
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07157514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07157514.